Nektar Therapeutics Interest Expense 2011-2025 | NKTR

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Nektar Therapeutics

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-6.25 M	-116 K	-162 K	6.85 M	21.3 M	21.6 M	22.1 M	22.5 M	18.3 M	17.9 M	18.5 M	15.5 M	10.2 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
22.5 M	-6.25 M	12.9 M

Quarterly Interest Expense Nektar Therapeutics

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	2.05 M	-	395 K	-	131 K	-	-	-	-	647 K	6.2 M	-	5.42 M	5.23 M	5.23 M	-	5.44 M	5.38 M	5.34 M	-	5.54 M	5.51 M	5.4 M	-	5.61 M	5.63 M	5.68 M	-	4.2 M	4.12 M	4.17 M	-	4.39 M	4.49 M	4.53 M	-	4.59 M	4.66 M	4.64 M	-	5.7 M	2.56 M	2.55 M	-2.52 M	2.54 M	2.57 M	2.58 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
6.2 M	-2.52 M	3.96 M

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Autolus Therapeutics plc AUTL	9.29 M	$ 1.87	11.68 %	$ 477 M	Britain
Aclaris Therapeutics ACRS	2.95 M	$ 3.0	-0.99 %	$ 232 M	USA
Alterity Therapeutics Limited ATHE	2.28 K	$ 3.1	-0.64 %	$ 7.46 B	Australia
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
Aeglea BioTherapeutics AGLE	-20.7 M	-	-	$ 1.01 B	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
AlloVir ALVR	1.19 M	-	4.14 %	$ 49.1 M	USA
Ascendis Pharma A/S ASND	65.5 M	$ 211.15	1.04 %	$ 5 B	Danmark
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
BioVie BIVI	4.3 M	$ 1.22	0.83 %	$ 1.8 M	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
BioDelivery Sciences International BDSI	-6 K	-	-4.8 %	$ 255 M	USA
Athersys ATHX	103 K	-	3.77 %	$ 22.4 M	USA
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Bellicum Pharmaceuticals BLCM	2.66 M	-	-9.72 %	$ 5.89 M	USA
Adaptimmune Therapeutics plc ADAP	-807 K	-	-15.15 %	$ 60.3 M	Britain
Can-Fite BioPharma Ltd. CANF	227 K	$ 0.17	-18.84 %	$ 370 M	Israel
Berkeley Lights BLI	910 K	-	-7.31 %	$ 87 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Catalyst Biosciences CBIO	1.04 M	$ 12.12	-1.86 %	$ 798 M	USA
Amphastar Pharmaceuticals AMPH	4.08 M	$ 26.86	-0.96 %	$ 1.3 B	USA
BeiGene, Ltd. BGNE	-12.6 M	-	0.49 %	$ 251 B	Cayman-islands
Calithera Biosciences CALA	2.65 M	-	-10.95 %	$ 876 K	USA
Certara CERT	-15.5 M	$ 8.85	-0.45 %	$ 1.42 B	USA
bluebird bio BLUE	16.4 M	-	-	$ 546 M	USA
Cellectis S.A. CLLS	371 K	$ 4.95	4.2 %	$ 116 M	France
Arena Pharmaceuticals ARNA	4.16 M	-	-6.81 %	$ 3.04 B	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
Axon Enterprise AXON	286 M	$ 583.1	-0.13 %	$ 44.2 B	USA
Aytu BioScience AYTU	-512 K	$ 2.55	4.08 %	$ 16 M	USA
ChromaDex Corporation CDXC	3 K	-	-0.88 %	$ 598 M	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Brickell Biotech BBI	5 K	-	-5.38 %	$ 6.06 M	USA
Celldex Therapeutics CLDX	927 K	$ 25.93	-1.8 %	$ 1.67 M	USA
Biohaven Pharmaceutical Holding Company Ltd. BHVN	-7.26 M	$ 11.43	2.65 %	$ 739 M	USA